slides-Highlights_of_Breast_Cancer__LocalRegionalAdjuvant [Autoguardado].pptx

•Download as PPTX, PDF•

0 likes•17 views

This document summarizes several presentations from the ASCO conference on breast cancer treatment. It discusses trials on omitting radiation therapy for certain breast cancer patients, using central Ki67 testing to guide treatment, using multi-gene assays to define patients who can safely avoid radiation, and predictive biomarkers for DCIS recurrence and response to radiation versus endocrine therapy. It also reviews a trial on adjuvant chemotherapy plus endocrine therapy versus endocrine therapy alone for older patients with ER-positive breast cancer, and an analysis of residual cancer burden after neoadjuvant immunotherapy and chemotherapy for triple-negative breast cancer.

Health & Medicine

ASCO Highlights of the Day<br />Breast Cancer Local/Regional/Adjuvant
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Highlights
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

LUMINA: A Prospective Trial Omitting Radiotherapy following Breast Conserving Surgery in T1N0 Luminal A Breast Cancer
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Slide 4
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Central Ki67 Testing
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Slide 6
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Slide 7
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Conclusions
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Is 5 years enough follow up?
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Are low ki67 patients low-risk or delayed risk?
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

“Low risk” by Multi-gene Assay Associated with Low LRR after Lumpectomy and WBI
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Can a Multi Gene Assay Define Breast Conservation Without RT?<br />Multiple Ongoing Clinical Trials
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

NRG BR007 Schema
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Slide 14
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Post-lumpectomy DCIS +/- Tamoxifen, <br />NSABP B-24
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

7-gene DCIS Biosignature Score
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

SweDCIS: Interaction analysis between DS and radiation therapy
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Study Population
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Patient distribution by 7-gene Biosignature Risk groups (3)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Adjuvant Radiation Therapy benefit within Biosignature Risk groups
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Adjuvant Endocrine Therapy effect within Biosignature Risk groups
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Final results from a phase III randomized clinical trial<br />of adjuvant endocrine therapy ± chemotherapy<br />in women ≥ 70 years old with ER+ HER2- breast cancer and a high
genomic grade index:<br />the Unicancer ASTER 70s trial
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Genomic Tools for BC and Older Patients
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

ASTER 70s Study Design<br />Adjuvant systemic treatment for ER+ HER2- BC in women over 70 according to GGI<br />Hypothesis: 4-year OS with CT ET > 4-year OS with ET only if
high GGI
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Statistical considerations
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Treatment Realization in Randomized Patients
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

OS: ET ── vs CT ET ── (ITT)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

OS: ET ── vs CT ET ── (per protocol)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Event-free Survival by Residual Cancer Burden After Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Early-Stage TNBC: Exploratory Analysis From
KEYNOTE-522
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

KEYNOTE-522 Study Design (NCT03036488)
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

EFS Analysis by RCB Category
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

EFS in RCB-2
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Summary and Conclusions
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Thank You!
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

The document discusses a study analyzing cell-free DNA (cfDNA) methylation as a predictive biomarker of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer patients. Researchers developed an mR-score biomarker using machine learning that predicted response to chemotherapy. The mR-scores were stable after chemotherapy started and may help stratify bladder cancer risk. Future studies aim to validate the risk stratification model and further explore the translational potential of cfDNA methylation analysis.

2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf

drblouse

Brachytherapy temporary vs permanent seed placement

Gil Lederman

This document compares temporary and permanent prostate brachytherapy seed placement for treating prostate cancer. It finds that permanent seed placement has better outcomes than temporary seed placement using catheters. For high-risk patients, the author's institution achieves 5 and 7-year disease-free survival rates up to 25% higher than another institution using temporary seed placement via catheters. Permanent seed placement allows patients to leave the hospital quickly with minimal side effects and return to normal activities, while temporary seed placement requires multiple treatments and hospital stays with more pain and risk of complications.

Wavelength October 2015 Volume 19 No. 2

Jerry Duncan

This article discusses the first clinical uses of Elekta's new Leksell Gamma Knife Icon system at University Hospital La Timone in Marseilles, France. The Icon allows for frameless Gamma Knife radiosurgery using a mask for head fixation rather than the traditional rigid frame. The first patient was treated on August 10th for a brain metastasis using this frameless approach. Additional patients were also treated for metastases. On August 17th, the first patient began a multi-session, hypofractionated treatment for a meningioma using the frameless approach. The Icon's advanced motion management and imaging capabilities enable these frameless treatments by precisely reproducing the patient's position over multiple sessions.

Local anaesthetic prescription for continuous nerve blocks

Amit Pawa

Comparison between anterior_cervical_dis

ramlugon khooshund

This document compares outcomes of anterior cervical discectomy fusion (ACDF) and anterior cervical corpectomy fusion (ACCF) for treating multi-level cervical spondylosis. It retrospectively analyzed 80 patients who underwent either multi-level ACDF (42 patients) or single/multi-level ACCF (38 patients) using titanium mesh cages filled with autograft and anterior cervical plates. The ACCF group had significantly higher blood loss and lower operative time than the ACDF group. Both groups showed equivalent improvement in symptoms, with fusion rates over 90% and maintained cervical lordosis. However, the ACCF group had a higher rate of early hardware failures and pseudarthroses.

Decision making between anterior skull base & lateral skull base

Murali Chand Nallamothu

1) The document discusses decision making approaches for tumors of the anterior and lateral skull base. It considers factors such as carotid control, nerve preservation, and minimizing brain retraction. 2) Key skull base surgeons like Kassam, Liu, Sanna, Sekhar, and Dugani provide expertise on various approaches and how the decision making has evolved over time with new techniques. 3) Carotid injury management is a critical topic, discussing options like covered stents, clamping, coiling, and the importance of revascularization when tumor resection jeopardizes the carotid artery.

2021-Stage-IV-NSCLC-Driver-Alteration-Slides.pptx

SigitSetiawan44

This document provides guidelines for treating stage IV non-small cell lung cancer (NSCLC) with known driver mutations. It discusses guidelines for first-line, second-line, and third-line or beyond treatment for NSCLC with mutations in EGFR, ALK, ROS1, BRAF, MET, RET, HER2, or NTRK. The guidelines were developed by an expert panel based on a review of literature. A total of 16 recommendations are provided for first-line treatment options for different driver mutations. The recommendations range from strong to weak based on evidence quality.

The document discusses dental care considerations for patients undergoing radiation therapy for head and neck cancers. It outlines that a dental examination should be performed before treatment to address any dental issues and reduce risks during and after radiation. Extractions should be completed 10-21 days before starting radiation to allow for healing. During radiation, dental care can help prevent oral complications like mucositis and xerostomia. Long term effects on the oral cavity are also discussed. The document emphasizes the importance of dental treatment planning and care coordination between dentists and oncologists for radiation therapy patients.

Radiation therapy patient treatment planning & post treatment care new

Indian dental academy

Rectal Cancer

Gil Lederman

This document discusses advances in non-invasive treatments for rectal cancer, allowing some patients to avoid colostomies and radical surgery. It describes a recent study of 36 patients with low-lying rectal cancer who received pre-operative radiation and chemotherapy, followed by surgery. For 5 patients (14%), the pre-operative treatment eliminated the cancer completely. Most patients (77%) were able to have a less invasive surgery called a low anterior resection, preserving their anus and avoiding a colostomy. The study concludes this approach may be a good alternative to more invasive surgeries for selected rectal cancer patients.

Latest Articles Published by Edorium Journals - July 2017

Edorium Journals

The open access journals published by Edorium Journals are international, peer reviewed, open access journals covering subjects in medical specialties, surgical specialties and basic sciences. These high quality open access academic journals give every author an avenue to publish their work in some of the best open access journals in medical and biomedical disciplines. http://www.edoriumjournals.com/

asco-cim2013 alsina.ppt

RobertojesusPerezdel1

The document summarizes several studies on ovarian cancer presented at the 2013 ASCO Annual Meeting. It discusses phase I/II trials of olaparib and cediranib combination therapy, paclitaxel/carboplatin with or without sorafenib as first-line treatment, bevacizumab and temsirolimus for recurrent ovarian cancer, and the effect of metformin on disease-free survival in diabetic ovarian cancer patients. It also mentions feasibility and safety studies of bevacizumab after neoadjuvant chemotherapy and metronomic chemotherapy for recurrent ovarian cancer.

Breast HDR interstitial brachytherapy

Ali Bagheri

This document provides information on breast interstitial brachytherapy workshop presented by Ali Bagheri M.D. and Cynthia Aristei M.D. It discusses clinical aspects of accelerated partial breast irradiation (APBI) including patient selection, techniques such as multi-catheter interstitial brachytherapy and balloon-based brachytherapy. It also covers target delineation, dose-fractionation schedules, dose constraints, and provides an example case of a 65 year old female who underwent lumpectomy and is a candidate for APBI using interstitial brachytherapy based on her pathology report and imaging.

International Journal of Case Reports and Images - January 2014

Edorium Journals

Standard care for breast cancer medical therapy

Prof. Shad Salim Akhtar

Early breast cancer is typically treated with surgery, radiation therapy, and systemic medical therapy according to standard protocols. The standard surgical treatment is complete excision of the breast cancer with negative margins along with lymph node dissection. Radiation therapy after breast-conserving surgery or mastectomy improves local control depending on risk factors. Systemic medical therapies include endocrine therapies like tamoxifen and ovarian ablation for hormone receptor positive disease as well as chemotherapy depending on risk. Optimal duration and timing of adjuvant treatments continues to be evaluated in ongoing clinical trials.

DR. SAHER SABRI

PAIRS WEB

This document discusses different mechanical atherectomy devices used to treat peripheral artery disease, including directional atherectomy devices like SilverHawk, orbital atherectomy devices like Diamondback, rotational atherectomy like Jetstream, and excimer laser atherectomy. It provides details on the types of lesions each device is best suited for and outcomes from studies on device safety and efficacy.

Aspirin as nanomedicine

Mewa Singh

The document discusses developing a new hybrid formulation of aspirin using nanoparticles to improve its solubility, absorption and bioavailability for cancer prevention and treatment. It aims to provide a safe, low-cost option for both reducing cancer risk and supporting patients by reducing pain, inflammation and improving quality of life. The hybrid works by inhibiting Cox-1 and Cox-2 enzymes to reduce prostaglandin production and inflammation, restricting the spread of cancer cells. It has completed proof of concept and early-stage development and requires further animal testing, manufacturing development and clinical trials before approval and commercialization.

behgal cancer institute

Dr Behgal K S

This document provides information about Dr. Behgal K.S., a director of the Behgal Cancer Centre and Behgal's Radiation Training Institute in Mohali, India. It discusses radiation therapy and brachytherapy facilities and techniques available at Behgal Cancer Centre, including linear accelerators, HDR brachytherapy, IMRT, IGRT, stereotactic radiosurgery, and nuclear medicine capabilities. The document also outlines various clinical applications of radiation therapy and brachytherapy techniques for different cancer types.

Scalp Cooling 101

bkling

In simplified terms, scalp cooling systems are tightly fitting, helmet-like hats filled with a cold gel or liquid that you wear during chemotherapy infusions. It is a device that can help many people keep some or quite a bit of their hair during chemotherapy which can cause hair loss. It has been life-changing for many in the cancer community, but not everyone can afford or has access to it. To help our breast (chest) cancer community understand how it works and its success rates, our guest speaker Julie Nangia, MD, Medical Director, Breast Oncology at Baylor College of Medicine, will discuss her clinical review published called "Quality of Life Matters: It Is Time to Integrate Scalp Cooling in Routine Clinical Practice" in JCO Oncology Practice: An American Society of Clinical Oncology Journal. Come with your questions and join us for this lively discussion.

Semirapid maxillary expansion

Indian dental academy

Srne sorrento therapeutics-redchip conference presentation (20140123)-reduced

RedChip Companies, Inc.

Sorrento Therapeutics presents its next-generation cancer therapeutics pipeline, including Cynviloq and RTX. Cynviloq is a late-stage paclitaxel product that offers potential advantages over Taxol and Abraxane such as higher dosing. It has demonstrated efficacy in multiple Phase 2 trials and is pursuing an abbreviated regulatory pathway for approval. RTX is a clinical stage non-opiate pain treatment that produces long-lasting analgesia through a single injection by targeting TRPV1 receptors. Sorrento aims to develop multiple products from RTX through intrathecal and intraganglionic injections.

Placement of dental_implants_in_irradiated_bone_the_case_for_using_hyperbaric...

Dr syed sohaib Gilani

This document discusses the use of hyperbaric oxygen therapy (HBO) prior to placing dental implants in patients who have received radiation therapy for cancer treatment. It begins by asking if there is a reason to use the osseointegrated implant (OI) concept in irradiated patients, and answers that implants can improve function and quality of life. However, placement of implants in irradiated bone can pose risks. The document then discusses factors related to radiation therapy and the patient that may affect implant outcomes, such as radiation dose, time since radiation, and bone quality. It concludes that HBO can help prevent potential complications in high-risk patients undergoing implant placement after radiation.

Carotid injury -Management in both Anterior & Lateral skull base

Murali Chand Nallamothu

The document discusses various options for managing carotid artery injury during anterior skull base surgery. It notes that covered stents, clamping, and coiling are the main options to cover a ruptured carotid. It emphasizes assessing collateral circulation with a balloon occlusion test preoperatively and considering pre-operative coiling for high-risk cases. Revascularization with a bypass is generally recommended if resection would jeopardize the carotid artery.

Astellas meeting, crpc- what we have in 2019

Mohamed Abdulla

1. The management of prostate cancer has undergone a paradigm shift with upfront intensified treatment of metastatic hormone-sensitive prostate cancer and the introduction of new treatment options for metastatic castrate-resistant prostate cancer. 2. Final analyses of trials such as LATITUDE and ARCHES showed a survival benefit of adding abiraterone or enzalutamide to androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer. 3. Trials such as PROSPER and SPARTAN demonstrated a delay in disease progression with the use of enzalutamide or apalutamide for non-metastatic castrate-resistant prostate cancer. 4. Questions remain about optimal treatment sequencing

Cancer diagnostics 2017: Scientific program

Cristina Fernandez

Aortic Association CBL Pilot April 19 – 20 Bern

suvadeepdas911

Light House Retreats: Plant Medicine Retreat Europe

Lighthouse Retreat

8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx

Holistified Wellness

We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.

NVBDCP.pptx Nation vector borne disease control program

Sapna Thakur

Histololgy of Female Reproductive System.pptx

AyeshaZaid1

Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

THERAPEUTIC ANTISENSE MOLECULES .pptx

70KRISHPATEL

Top-Vitamin-Supplement-Brands-in-India List

SwisschemDerma

Recently uploaded (20)

Aortic Association CBL Pilot April 19 – 20 Bern

Light House Retreats: Plant Medicine Retreat Europe

Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad

share - Lions, tigers, AI and health misinformation, oh my!.pptx

Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun

Tests for analysis of different pharmaceutical.pptx

Novas diretrizes da OMS para os cuidados perinatais de mais qualidade

How STIs Influence the Development of Pelvic Inflammatory Disease.pptx

A Classical Text Review on Basavarajeeyam

CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf

Adhd Medication Shortage Uk - trinexpharmacy.com

Best Ayurvedic medicine for Gas and Indigestion

CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf

Osteoporosis - Definition , Evaluation and Management .pdf

8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx

NVBDCP.pptx Nation vector borne disease control program

Histololgy of Female Reproductive System.pptx

Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx

THERAPEUTIC ANTISENSE MOLECULES .pptx

Top-Vitamin-Supplement-Brands-in-India List

slides-Highlights_of_Breast_Cancer__LocalRegionalAdjuvant [Autoguardado].pptx

1. ASCO Highlights of the Day Breast Cancer Local/Regional/Adjuvant Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

2. Highlights Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

3. LUMINA: A Prospective Trial Omitting Radiotherapy following Breast Conserving Surgery in T1N0 Luminal A Breast Cancer Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

4. Slide 4 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

5. Central Ki67 Testing Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

6. Slide 6 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

7. Slide 7 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

8. Conclusions Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

9. Is 5 years enough follow up? Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

10. Are low ki67 patients low-risk or delayed risk? Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

11. “Low risk” by Multi-gene Assay Associated with Low LRR after Lumpectomy and WBI Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

12. Can a Multi Gene Assay Define Breast Conservation Without RT? Multiple Ongoing Clinical Trials Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

13. NRG BR007 Schema Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

14. Slide 14 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

15. Post-lumpectomy DCIS +/- Tamoxifen, NSABP B-24 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

16. 7-gene DCIS Biosignature Score Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

17. SweDCIS: Interaction analysis between DS and radiation therapy Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

18. Study Population Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

19. Patient distribution by 7-gene Biosignature Risk groups (3) Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

20. Adjuvant Radiation Therapy benefit within Biosignature Risk groups Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

21. Adjuvant Endocrine Therapy effect within Biosignature Risk groups Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

22. Conclusions Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

23. Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: the Unicancer ASTER 70s trial Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

24. Genomic Tools for BC and Older Patients Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

25. ASTER 70s Study Design Adjuvant systemic treatment for ER+ HER2- BC in women over 70 according to GGI Hypothesis: 4-year OS with CT ET > 4-year OS with ET only if high GGI Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

26. Statistical considerations Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

27. Treatment Realization in Randomized Patients Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

28. OS: ET ── vs CT ET ── (ITT) Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

29. OS: ET ── vs CT ET ── (per protocol) Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

30. Conclusions Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

31. Event-free Survival by Residual Cancer Burden After Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Early-Stage TNBC: Exploratory Analysis From KEYNOTE-522 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

32. KEYNOTE-522 Study Design (NCT03036488) Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

33. EFS Analysis by RCB Category Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

34. EFS in RCB-2 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

35. Summary and Conclusions Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

36. Thank You! Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

slides-Highlights_of_Breast_Cancer__LocalRegionalAdjuvant [Autoguardado].pptx

Recommended

Recommended

More Related Content

Similar to slides-Highlights_of_Breast_Cancer__LocalRegionalAdjuvant [Autoguardado].pptx

Similar to slides-Highlights_of_Breast_Cancer__LocalRegionalAdjuvant [Autoguardado].pptx (20)

Recently uploaded

Recently uploaded (20)

slides-Highlights_of_Breast_Cancer__LocalRegionalAdjuvant [Autoguardado].pptx